Compare Moody's Corporation (MCO) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moody's Corporation vs Novartis AG — how do they compare? Moody's Corporation trades at $460.39 (market cap $77.87B), while Novartis AG trades at $142.04 (market cap $274.00B). The key difference: Novartis AG is far larger — about 3.5× Moody's Corporation's market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Moody's Corporation for 132 Days and Novartis AG for 82 Days on average.
| MCO | NVS | |
|---|---|---|
Market Cap | $77.87B | $274.00B |
Volume | 633,412 | 1,852,137 |
Sector | Financials | Health |
52-Week High | $539.61 | $168.62 |
52-Week Low | $412.23 | $121.80 |
Typical Hold Time | 132 Days | 82 Days |
Enterprise Value | $83.89B | $315.32B |
Dividend Yield | 0.92% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moody's Corporation (MCO) trades at $458.69, up 1.41% with strong fundamentals including 34.25% net income margin and 80.15% ROE. The stock shows bearish technical signals but has consistently beaten earnings estimates in recent quarters. Recent developments include a minority stake acquisition in Philippine Rating Services and continued leadership in risk analytics, with the company ranking #1 in Chartis RiskTech100 for the fifth consecutive year.
Despite technical weakness, Moody's maintains strong profitability and analyst support with 56% buy ratings and a $536.40 consensus target. Key risks include high valuation multiples and potential market volatility, but the company's dominant market position and consistent earnings growth support long-term investment appeal.
Novartis (NVS) trades at $143.11, up 1.65% with mixed technical signals showing neutral momentum. The company maintains strong profitability with 22.5% net margins and recently announced a $7.8B licensing deal with China's Abogen. Recent earnings show two beats and one miss in the last three quarters, with Q3 2026 results pending. The stock trades below the consensus price target of $146, suggesting modest upside potential from current levels.
Novartis presents a balanced investment case with strong cash flow generation and profitability offset by recent clinical setbacks and M&A scrutiny. The $7.8B Abogen partnership expands the autoimmune pipeline, but investors face risks from patent cliffs and drug development failures. Analyst consensus leans cautious with 68% hold ratings, reflecting uncertainty around pipeline execution amid ongoing strategic repositioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
